JP2024516929A5 - - Google Patents
Info
- Publication number
- JP2024516929A5 JP2024516929A5 JP2023557096A JP2023557096A JP2024516929A5 JP 2024516929 A5 JP2024516929 A5 JP 2024516929A5 JP 2023557096 A JP2023557096 A JP 2023557096A JP 2023557096 A JP2023557096 A JP 2023557096A JP 2024516929 A5 JP2024516929 A5 JP 2024516929A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- formulation according
- agent
- amount sufficient
- produce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21166691.2 | 2021-04-01 | ||
| EP21166691 | 2021-04-01 | ||
| PCT/EP2022/058523 WO2022207773A1 (en) | 2021-04-01 | 2022-03-31 | Laquinimod formulation for ocular use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516929A JP2024516929A (ja) | 2024-04-18 |
| JP2024516929A5 true JP2024516929A5 (enExample) | 2025-03-27 |
Family
ID=75362492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557096A Pending JP2024516929A (ja) | 2021-04-01 | 2022-03-31 | 眼用ラキニモド製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240180819A1 (enExample) |
| EP (2) | EP4461364B1 (enExample) |
| JP (1) | JP2024516929A (enExample) |
| KR (1) | KR20230165260A (enExample) |
| CN (1) | CN117120035A (enExample) |
| AU (1) | AU2022248724A1 (enExample) |
| BR (1) | BR112023018932A2 (enExample) |
| CA (1) | CA3212851A1 (enExample) |
| ES (1) | ES3014261T3 (enExample) |
| IL (1) | IL305997A (enExample) |
| MX (1) | MX2023010971A (enExample) |
| PL (1) | PL4312986T3 (enExample) |
| WO (1) | WO2022207773A1 (enExample) |
| ZA (1) | ZA202309969B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL320428A (en) | 2022-11-04 | 2025-06-01 | Qlaris Bio Inc | Topical ophthalmic administration of cromolyns |
| CN118892446A (zh) * | 2023-04-27 | 2024-11-05 | 维眸生物科技(浙江)有限公司 | 一种含vvn001的眼科组合物 |
| CN119523881A (zh) * | 2024-04-28 | 2025-02-28 | 中国人民解放军海军军医大学第二附属医院 | 一种s100a9抑制剂凝胶剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| EP3068395A4 (en) * | 2013-11-15 | 2017-07-12 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| US9694003B2 (en) * | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| IL289109B2 (en) * | 2019-06-19 | 2025-10-01 | Tarsus Pharmaceuticals Inc | Isoxazoline formulations against parasites and methods for treating blepharitis |
| KR20220118419A (ko) | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물 |
-
2022
- 2022-03-31 PL PL22718720.0T patent/PL4312986T3/pl unknown
- 2022-03-31 US US18/284,284 patent/US20240180819A1/en active Pending
- 2022-03-31 KR KR1020237035464A patent/KR20230165260A/ko active Pending
- 2022-03-31 CA CA3212851A patent/CA3212851A1/en active Pending
- 2022-03-31 ES ES22718720T patent/ES3014261T3/es active Active
- 2022-03-31 CN CN202280022389.2A patent/CN117120035A/zh active Pending
- 2022-03-31 JP JP2023557096A patent/JP2024516929A/ja active Pending
- 2022-03-31 BR BR112023018932A patent/BR112023018932A2/pt unknown
- 2022-03-31 IL IL305997A patent/IL305997A/en unknown
- 2022-03-31 MX MX2023010971A patent/MX2023010971A/es unknown
- 2022-03-31 AU AU2022248724A patent/AU2022248724A1/en active Pending
- 2022-03-31 EP EP24203145.8A patent/EP4461364B1/en active Active
- 2022-03-31 EP EP22718720.0A patent/EP4312986B1/en active Active
- 2022-03-31 WO PCT/EP2022/058523 patent/WO2022207773A1/en not_active Ceased
-
2023
- 2023-10-25 ZA ZA2023/09969A patent/ZA202309969B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102958509B (zh) | 用于不含防腐剂的非粘性前列腺素类溶液的聚合物给药系统 | |
| JP2024516929A5 (enExample) | ||
| JP2011516537A (ja) | 安定性のある眼科用の製剤 | |
| CN114245737A (zh) | 微乳剂组合物 | |
| RU2744570C2 (ru) | Фармацевтическая композиция на основе трамадола для офтальмологического применения | |
| RU2700927C2 (ru) | Офтальмологическая композиция, содержащая циклоспорин и трегалозу | |
| CN103747786A (zh) | 比马前列素和溴莫尼定的固定剂量组合 | |
| US20120277239A1 (en) | Compositions and Methods for Improving Night Vision | |
| JP2017501224A (ja) | 緑内障の治療用組成物及び方法 | |
| IL305997A (en) | Laquinimod formulation for ocular use | |
| JP2021091697A (ja) | 水性点眼点鼻用組成物 | |
| WO2016171152A1 (ja) | 角膜障害の治療剤、改善剤または予防剤 | |
| US20090209599A1 (en) | Eye drop containing roflumilast | |
| JP6407145B2 (ja) | 網脈絡膜障害の抑制剤 | |
| JP4737911B2 (ja) | 点眼剤 | |
| CN110785162B (zh) | 用于治疗青光眼的滴眼液组合物 | |
| KR102444571B1 (ko) | 세티리진 및 토코페솔란을 포함하는 안과용 조성물 | |
| JPH06172158A (ja) | 眼房水の上昇した眼圧を低下させるための眼科用液剤 | |
| CN110913867B (zh) | 热凝胶化人工泪液 | |
| JP2011512362A (ja) | 眼科応用のためのフルオロキノロン誘導体 | |
| TW201705956A (zh) | 唑系抗真菌藥之對眼瞼皮膚的投與 | |
| WO2018056268A1 (ja) | 炎症性眼疾患の治療及び／又は予防剤 | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| KR20210108877A (ko) | 류코트리엔 수용체 차단제를 유효성분으로 포함하는 안압 하강용 점안제 조성물 | |
| JP2013129604A (ja) | 緑内障治療薬を含有する徐放性フィルム製剤 |